LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng… - Bioscience …, 2017 - portlandpress.com
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway.
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng… - Bioscience …, 2017 - europepmc.org
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway.
P Du, H Zhao, R Peng, Q Liu, J Yuan… - Bioscience …, 2017 - search.ebscohost.com
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
[PDF][PDF] LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng, Y Liao - 2017 - pdfs.semanticscholar.org
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
[PDF][PDF] LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng, Y Liao - 2017 - scienceopen.com
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan… - Bioscience …, 2017 - pubmed.ncbi.nlm.nih.gov
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
[HTML][HTML] LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng… - Bioscience …, 2017 - ncbi.nlm.nih.gov
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …